Earnings call transcript: Twist Bioscience Q2 2026 EPS miss, stock rises

Twist Bioscience reported Q2 FY2026 revenue of $110.7 million, up 19.3% year over year, with gross margin expanding 200 bps to 51.6% and management reaffirming a path to adjusted EBITDA breakeven in Q4 FY2026. The offset was a sharp EPS miss at -$0.71 versus -$0.48 expected, alongside $95.8 million of operating expenses and a $17.1 million litigation settlement. Shares still rose 1.21% premarket to $61.13 as investors focused on strong AI-enabled therapeutics growth, NGS momentum, and improved margins.

Analysis

TWST’s quarter reads like an execution inflection rather than a simple revenue beat: the business is moving from “growth at any cost” toward a more scalable mix where incremental demand increasingly monetizes through higher-value workflows. The important second-order signal is that AI-linked discovery is no longer a handful of pilot accounts; it is broadening into repeat behavior, which should raise revenue durability and lower the probability that one or two programs drive the narrative. That matters because it changes the multiple from “tool vendor exposed to project volatility” toward “platform compounding inside a workflow.”

The market is likely underappreciating the leverage embedded in broader sequence acceptance. If management can actually convert the higher acceptance rate into order capture, the upside is not just more top-line; it is better utilization of the existing commercial funnel and less customer leakage to specialized competitors. The near-term risk is that the Street may extrapolate margin expansion too linearly while the company keeps spending into backend automation, characterization capacity, and digital infrastructure — those investments are necessary, but they also mean the path to EBITDA breakeven can be noisy quarter to quarter.

From a trading standpoint, the cleanest read is that sentiment is positive but not yet euphoric, so the move may still be under-owned by growth funds. The contrarian concern is that the current valuation likely embeds a smooth H2 acceleration and successful conversion of AI bookings into repeatable revenue; if NGS or DSPS growth moderates even modestly, the stock can de-rate quickly because expectations have shifted from “good story” to “prove the slope.” Longer term, the litigation settlement removes a cash overhang, but the real catalyst is the next two quarters of evidence that higher-complexity products can scale without gross margin slippage.

Key Decisions for Investors

• Go long TWST on a 1-3 month horizon on pullbacks of 3-5% from post-earnings levels; risk/reward is attractive if management confirms AI-driven demand is broadening and Q3 revenue lands in range, but trim if gross margin stalls below the low-51% area.
• Buy TWST Jan-2026 calls or call spreads to express upside from a successful H2 acceleration; favor 55/70 or 60/80 structures to monetize a multiple expansion if acceptance-rate improvements translate into visible order capture.
• Pair trade: long TWST / short a basket of slower-growth life science tools names with weaker AI exposure over the next 1-2 quarters; TWST should outperform if investors rotate toward platform names with visible revenue compounding and margin inflection.
• Use put spreads as a hedge against a guidance-reset event if NGS sequential growth disappoints in the next print; the most likely bear case is not demand collapse but a normalization of order timing and slower conversion of AI-related backlog.
• Watch for confirmation that sequential OpEx improvement is real by the next quarter; if EBITDA losses do not narrow as planned, consider taking profits on any post-earnings strength because the breakeven story is the main support for the current premium.